% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Judickiene:310293,
      author       = {J. Judickiene and M. Metzenmacher and G. Zaun and M.
                      Wiesweg and D. E. Meschke and N. Guberina and F. Oezkan and
                      J. Hense and M. Schuler$^*$ and D. Theegarten and S.
                      Bolükbas and M. Stuschke and W. E. E. Eberhardt},
      title        = {{P}retherapeutic prognostic factors for survival under
                      chemoimmunotherapy/immunotherapy of advanced {NSCLC}
                      patients.},
      journal      = {European journal of cancer},
      volume       = {238},
      issn         = {0959-8049},
      address      = {Amsterdam [u.a.]},
      publisher    = {Elsevier},
      reportid     = {DKFZ-2026-00516},
      pages        = {116600},
      year         = {2026},
      abstract     = {Checkpoint inhibitor therapy with PD-1/PD-L1-antibodies has
                      significant benefits in non-small-cell lung cancer treatment
                      even in advanced stage IVA/B. While PD-L1 expression in
                      tumor is a weak but relevant predictor of treatment
                      response, impact and interaction of potential prognostic
                      factors like ECOG status, LDH-levels, CRP-levels, and
                      genetic mutations remain so far undefined. This study aims
                      to identify pretherapeutic factors that could help estimate
                      outcome of NSCLC patients undergoing chemoimmunotherapy or
                      mono-immunotherapy.In our Comprehensive Cancer Centre we
                      retrospectively analyzed two selective patient groups
                      undergoing treatment with mono- or chemoimmunotherapy.
                      'Super responders' with long-term survival longer than 24
                      months were contrasted against primary progressors with
                      progression-free survival of less than 10 months. Factors
                      were analyzed with univariate and multivariate statistical
                      methods.In 120 patients fulfilling the inclusion criteria we
                      found signals for five factors with impact on overall
                      survival in univariate analyses: ECOG-status, PD-L1 TPS,
                      serum LDH, serum CRP and KEAP-1 mutation. Multivariate
                      analyses confirmed independent impact. As a confirmatory
                      analysis the impact of these factors on progression-free
                      survival was investigated. Comparable impact was supported
                      by univariate and multivariate analysis.A detailed
                      prognostic factor analysis for overall survival and
                      progression-free survival in selected groups of advanced
                      non-small-cell lung cancer patients under chemo- or
                      mono-immunotherapy identified five independent parameters:
                      initial ECOG of zero, non-elevated LDH, non-elevated CRP,
                      pretreatment PD-L1 positivity and absence of KEAP1-mutation.
                      Our findings are especially helpful of estimating early
                      treatment failure with aggressive lung cancer progression.
                      This important investigation will be prospectively confirmed
                      in a larger, more unselected population at our Cancer
                      Centre.},
      keywords     = {Lung cancer - NSCLC - stage IV - pretreatment prognostic
                      factors - immunotherapy (Other)},
      cin          = {ED01},
      ddc          = {610},
      cid          = {I:(DE-He78)ED01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:41780180},
      doi          = {10.1016/j.ejca.2026.116600},
      url          = {https://inrepo02.dkfz.de/record/310293},
}